AlivaMab Biologics Offers Royalty-Free Access to Transgenic Mouse Platform for Human Antibody Discovery
核心洞察
AlivaMab Biologics (搜索) announced that its AlivaMab Mouse (搜索) platform, featuring transgenic mice for fully human antibody (搜索) drug discovery, is now available on a license-, milestone- and royalty-free basis for service partners.
The platform includes AlivaMab Mouse (搜索)-NGX strains for human IgH/IgL antibody discovery and AlivaMab Mouse-SDX strains for human single domain antibody (搜索) discovery, offered through fee-for-service arrangements.
The company provides fully integrated solutions for biologics drug discovery and engineering, including reagent generation, functional assay development, immune repertoire analysis, and antibody engineering capabilities.
AlivaMab Biologics (搜索), LLC announced that its AlivaMab Mouse (搜索) platform, a suite of transgenic mice designed for fully human antibody (搜索) drug discovery, is now available on a license-, milestone- and royalty-free basis for partners engaging the company for antibody drug discovery and engineering services.
Platform Capabilities and Offerings
The AlivaMab Mouse (搜索) platform encompasses two distinct strains optimized for different antibody discovery approaches. The AlivaMab Mouse-NGX strains are designed for human IgH/IgL antibody drug discovery, while the AlivaMab Mouse-SDX strains focus on human single domain antibody (搜索) discovery. Both platforms are offered through fee-for-service arrangements without additional licensing costs.
"We are thrilled to offer the newest generations of AlivaMab Mouse (搜索), the most advanced platforms for human antibody (搜索) drug discovery, to our partners free of any license or downstream economics," said Larry Green, Chief Executive Officer of AlivaMab Biologics (搜索). "We are passionate about applying our experience and know-how for scientifically driven and efficient antibody drug discovery and engineering for our partners."
Comprehensive Service Portfolio
AlivaMab Biologics (搜索) provides fully integrated solutions for biologics drug discovery and engineering through fit-for-purpose workflows and modular capabilities. The company's service offerings include reagent generation and validation, sophisticated functional assay development and execution, and advanced methodologies for deep immune repertoire recovery and interrogation.
Additional capabilities encompass kinetic and epitope characterization, antibody engineering, full developability assessment, and production up to medium scale. The company's approach enables complete outsourcing of antibody drug discovery and engineering processes for pharmaceutical partners.
Strategic Business Model
The company operates through flexible engagement models, offering both end-to-end solutions and à la carte services to accommodate varying partner needs. According to Green, AMB's fee-for-service model with the transgenic mouse platforms delivers "unmatched speed and value in the race to get best-in-class biologics drugs to market."
The service structure aims to accelerate discovery timelines while providing what the company describes as the most de-risked path to success through discovery and development phases. Partners benefit from the team's experience across various biologics modalities, supported by the company's established track record in the field.